A Review on the Role of Moxifloxacin in the Treatment and Management of Respiratory Tract Infections
Abstract
Respiratory tract infections (RTIs) constitute a major global health burden, with significant impact on morbidity and mortality rates, particularly among vulnerable populations. Moxifloxacin, a fourth-generation fluoroquinolone, is an important antibiotic for treating various RTIs, including community-acquired pneumonia (CAP), acute exacerbations of chronic bronchitis (AECB), and acute bacterial sinusitis. The drug exhibits potent activity against key respiratory pathogens, including drug-resistant Streptococcus pneumoniae, Haemophilus influenzae, and atypical organisms. Its dual mechanism of action targeting bacterial DNA gyrase and topoisomerase IV, combined with favorable pharmacokinetic properties such as high bioavailability and extensive tissue penetration, contributes to its clinical effectiveness. Once-a-daily dose and the ability to switch between oral and intravenous formulations enhance its therapeutic utility. Clinical studies demonstrate comparable or superior efficacy to standard treatments across various RTIs. However, safety considerations include QT interval prolongation, tendinopathy risk, and rare cases of hepatotoxicity, necessitating careful patient selection and monitoring. The emergence of bacterial resistance mechanisms, including mutations in quinolone resistance-determining regions and efflux pumps, requires judicious use to maintain long-term effectiveness. Current evidence indicates that moxifloxacin is a valuable antimicrobial agent for RTIs,…
Read the paper
Related studies
- Structural and topological analysis of thiosemicarbazone-based metal complexes: computational and experimental study of bacterial biofilm inhibition and antioxidant activity
- Toward better cures for Mycobacterium abscessus lung disease
- Challenges for global antibiotic regimen planning and establishing antimicrobial resistance targets: implications for the WHO Essential Medicines List and AWaRe antibiotic book dosing
- Design, Synthesis and In vitro Antitubercular Effect of New Chalcone Derivatives Coupled with 1,2,3‐Triazoles: A Computational Docking Techniques
- Upregulation of pmrA, pmrB, pmrC, phoQ, phoP, and arnT genes contributing to resistance to colistin in superbug Klebsiella pneumoniae isolates from human clinical samples in Tehran, Iran
- Whole-genome sequencing of clinical isolates of Citrobacter Europaeus in China carrying blaOXA−48 and blaNDM−1
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.